Sun Pharma Q4 net more than doubles to Rs 894 cr; declares dividend of Rs 2




on Thursday reported 123 per cent year-on-year increase in consolidated net profit at Rs 894 crore for the quarter ending March 31, 2021. It was Rs 399.8 crore in the year-ago period.


However, the profit was still below the Street’s expectation of over Rs 1,200 crore. has incurred an exceptional loss of Rs 672.8 crore related to various litigation settlements pertaining to some of its subsidiaries.



Its revenue from operations came in at Rs 8,522 crore for the quarter under review, an increase of 4 per cent from Rs 8,184 crore in the same quarter last year.


Meanwhile, other income for the March quarter is at Rs 111 crore. At the operating level, earnings before interest, tax, deprecitation and amortisation (EBITDA) stood at Rs 2,048 crore, with margins of 24.3 per cent.


The company’s board has recommended a final dividend of Rs 2 per share for the financial year ended March, 2021.


Ahead of the results, the company’s scrip was down 0.47 per cent at Rs 700.5 on NSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor



Leave a Reply

Your email address will not be published. Required fields are marked *

WP Twitter Auto Publish Powered By : XYZScripts.com